Sugi Predict

Sugi Predict / Compounds / SCHEMBL1479970

SCHEMBL1479970

SCHEMBL1479970

NC(=O)CCCc1cccs1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.69
▸ POLB P06746 3/20 0.69
▸ TSHR P16473 3/20 0.69
▸ ALDH1A1 P00352 1/20 0.69
▸ L3MBTL1 Q9Y468 1/20 0.69
▸ TAAR1 Q96RJ0 1/20 0.59
▸ ADRA2A P08913 3/20 0.53
▸ ADRA2B P18089 3/20 0.53
▸ ADRA2C P18825 3/20 0.53
▸ NPC1 O15118 4/20 0.51
▸ CASP3 P42574 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.49
▸ RAB9A P51151 3/20 0.48
▸ CYP2C19 P33261 1/20 0.47
▸ NAMPT P43490 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ MC4R P32245 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477189 0.94 POLB (0.72) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL30884578 0.93 POLB (0.70) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL1477454 0.90 POLB (0.62) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL5353444 0.89 POLB (0.60) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL27987587 0.86 TAAR1 (0.55) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL338927 0.85 NPC1 (0.68) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL7674009 0.83 TAAR1 (0.52) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL11633870 0.83 NPC1 (0.66) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL6790790 0.83 TAAR1 (0.52) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1
SCHEMBL9205353 0.83 TAAR1 (0.52) SMN1; SMN2POLBTSHRALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 — — US claimed
CN-102702194-A Anti-viral compounds ABBOTT LAB 2012-10-03 — — CN claimed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 — — US claimed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 — — EP claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 — — EP claimed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 — — US claimed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 — — WO claimed
CN-1867572-A proteasome inhibitors and methods of use thereof CEPHALON INC (US) 2006-11-22 — — CN claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 — — WO claimed
US-20240189360-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS PHARMA INC. (US) 2024-06-13 — — US disclosed
US-11311619-B2 Integrin activator vaccine compositions 7 Hills Pharma Inc. and Texas Heart Institute (US) 2022-04-26 — — US disclosed
CN-1090581-A The preparation method of the novel derivative of erythromycin and they and as the application of medicine ROUSSEL UCLAF (FR) 1994-08-10 — — CN disclosed
EP-0596802-A1 Erythromycin derivatives, their process of preparation and their application as medicaments ROUSSEL UCLAF (FR) 1994-05-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11311619-B2 Integrin activator vaccine compositions ITGAM, ITGA2B, ITGA1 SMN1; SMN2 2358/4885POLB 3433/4885TSHR 1793/4885
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 SMN1; SMN2 1107/4885POLB 829/4885TSHR 4250/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 SMN1; SMN2 1107/4885POLB 829/4885TSHR 4250/4885
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SMN1; SMN2 3135/4885POLB 442/4885TSHR 4805/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 SMN1; SMN2 3135/4885POLB 442/4885TSHR 4805/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 SMN1; SMN2 1107/4885POLB 829/4885TSHR 4250/4885
US-20240189360-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS CXCL12, ITGB3, ITGB7 SMN1; SMN2 375/4885POLB 1947/4885TSHR 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.